Chemotherapeutic drugs acting as immunogenic cell death (ICD) inducers show promise in transforming the immunosuppressive tumor microenvironment into immune-responsive tumors, with their efficacy enhanced through nanomedicine to overcome poor pharmacokinetics and tumor targeting. Tumor-activated, carrier-free prodrug nanoparticles (PDNPs) offer a solution to conventional nanoparticle limitations, improving drug delivery safety and effectiveness, and when combined with other therapies, significantly enhance responses to immune checkpoint blockade therapy.
Cell Systems is a monthly peer-reviewed scientific journal covering research in systems biology. The journal was established in 2015 and published by Cell Press. According to the Journal Citation Reports, the journal has a 2021 impact factor of 11.091.
Chem is a peer-reviewed scientific journal by Cell Press. It is a sister journal to Cell. It was established in 2016, and is currently edited by Dr. Robert Eagling. Current IF is around 26.
This systematic review highlights the distinction between the prevalence and incidence of type 2 diabetes, noting that while prevalence guides resource allocation, prevention focuses on reducing incidence. Their analysis across over 100 populations indicates that, despite a consistent increase in incidence until 2005, recent data shows a mix of decreasing and stable incidence rates, possibly reflecting effective diabetes prevention measures. However, the review also suggests that without addressing the underlying issues of weight gain, overweight, and obesity, the incidence of type 2 diabetes is unlikely to decrease significantly, especially in the context of continued high obesity rates in the US and the emerging impact of Western diets in low and middle-income countries.
The global rise in obesity and type 2 diabetes mellitus (T2DM) threatens to reverse progress in combating cardiovascular disease (CVD). Recent evidence highlights the importance of cardiologists in the proactive management of T2DM, given the clear benefits of certain medications in reducing CVD risks. Research emphasizes the urgent need for earlier and more aggressive treatment of T2DM, especially in younger patients, to mitigate their significantly higher risk of CVD. However, challenges such as inadequate training for cardiologists in managing these conditions and the need for healthcare system reforms to better accommodate cardiometabolic disease management are identified as major obstacles to adopting this new treatment paradigm.
Cell Press has launched a series of symposia that are compact scientific meetings curated by Cell Press editors to highlight cutting-edge research and provide unique networking with preeminent speakers and experts in your field. This is the link: https://www.cell.com/symposia
I just check their website, currently, there are no open Grant Opportunities at this time. They used to fund a lot of different projects related to global public health projects. Not sure they will have it in the future.
HHMI is one of the largest philanthropic organizations in the world, known for its long-term investment in fundamental research and scientists. It is so prestigious that they recruit very top scientists.
Ubiquitin-specific proteases (UBPs), a category of deubiquitinases (DUBs), are crucial for regulating plant development and stress responses, though their functional mechanisms largely remain to be elucidated. Recent progress in identifying UBPs' functional partners and understanding their molecular interactions offers promising avenues for uncovering the roles of protein deubiquitination in plants, potentially leading to a deeper comprehension of UBPs' physiological importance.
Ubiquitin-specific peptidases (USPs) play a crucial role in the etiology and progression of breast cancer, representing promising therapeutic targets. This review highlights the involvement of various USPs in breast cancer and summarizes the inhibitors investigated for treatment, emphasizing the potential of USPs as a focus for developing effective therapies despite none being clinically approved yet.
Ubiquitination and deubiquitination are key reversible processes that affect protein characteristics, with ubiquitin-specific proteases (USPs) playing a significant role in metabolic diseases by either improving or worsening conditions like hyperglycemia, diabetic nephropathy, NAFLD, and atherosclerosis. USPs have both positive and negative impacts on these conditions, with specific USPs associated with various effects in different tissues, indicating their complex roles in energy metabolism and related disorders.
Ubiquitin-specific proteases are deubiquitinating enzymes involved in the removal of ubiquitin from specific protein substrates resulting in protein salvage from proteasome degradation, regulation of protein localization or activation. DNA alteration and overexpression in different cancer types, as well as involvement in many cancer-associated pathways, make ubiquitin-specific proteases attractive for the cancer drug discovery purposes. Their proteolytic function associated to available structural biology data reinforce their potential for pharmacological interference. The authors reviewed this class of enzymes as cancer drug targets in terms of validation and draggability.
Breast cancer (BC), the leading cause of cancer death among women, sees 30% of cases advancing to metastatic disease, with current treatments unable to cure and average survival around 2 years. Recent advances in adoptive cell therapy, specifically NK and CAR-NK cell immunotherapy, offer new hope for BC treatment through targeting cancer cells with enhanced immune responses without harming healthy cells.
The development of allogeneic natural killer (NK) cell therapies for cancer treatment, particularly against hematologic malignancies, has advanced with clinical trials exploring NK cells derived from various sources. Recent progress includes genetic enhancements for better tumor targeting and methods to increase the expansion and persistence of induced pluripotent stem cell (iPSC)-derived NK cells, promising future improvements in NK cell-based treatments for both hematologic and solid tumors.
Article